share_log

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax製藥 | 10-K/A：年度報表(修正版)
美股SEC公告 ·  10/10 14:10

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax藥品公司，一家處於臨床前階段的藥品公司，報告稱截至2022年12月31日止的年度淨損失爲2170萬美元，而上一年淨損失爲1210萬美元。該公司的累積赤字達到約4440萬美元。儘管出現虧損，Virpax約有1900萬美元的現金儲備。公司正涉及一起可能達到3500萬美元賠償的訴訟，但已爲此目的計提了200萬美元。Virpax資本的主要來源是通過發行股票，包括在2021年成功進行的首次公開募股（IPO）和一項承銷的公開發行。公司的基本報表是在假設其將繼續作爲持續經營實體而編制的，儘管由於持續虧損和訴訟不確定性存在重大疑慮。Virpax專注於開發非阿片類疼痛管理治療和中樞神經系統疾病治療。該公司依賴第三方合同製造組織（CMO）進行生產，並已與各種研究和許可協議達成協議以推進其產品候選者。
Virpax藥品公司，一家處於臨床前階段的藥品公司，報告稱截至2022年12月31日止的年度淨損失爲2170萬美元，而上一年淨損失爲1210萬美元。該公司的累積赤字達到約4440萬美元。儘管出現虧損，Virpax約有1900萬美元的現金儲備。公司正涉及一起可能達到3500萬美元賠償的訴訟，但已爲此目的計提了200萬美元。Virpax資本的主要來源是通過發行股票，包括在2021年成功進行的首次公開募股（IPO）和一項承銷的公開發行。公司的基本報表是在假設其將繼續作爲持續經營實體而編制的，儘管由於持續虧損和訴訟不確定性存在重大疑慮。Virpax專注於開發非阿片類疼痛管理治療和中樞神經系統疾病治療。該公司依賴第三方合同製造組織（CMO）進行生產，並已與各種研究和許可協議達成協議以推進其產品候選者。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間